Ipsen joins the ADC club with deal worth up to $900m
Ipsen signed a licensing agreement to develop and commercialise Sutro Biopharma’s ADC STRO-003 intended as a treatment for solid tumours.
Ipsen signed a licensing agreement to develop and commercialise Sutro Biopharma’s ADC STRO-003 intended as a treatment for solid tumours.
What's Your Reaction?
